Thomas Mandat, MD
Internal Medicine · Parma, OHNPI 1881792794
Payments from drug & device makers
Across 92 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$222
- Biohaven Pharmaceutical Holding Company Ltd.$165
- Biohaven Pharmaceuticals, Inc.$163
- AbbVie$159
- Johnson & Johnson$159
- Avanir Pharmaceuticals, Inc.$86
- plus $843 from 30 others
What the payments were for
- Food & beverage$1,71195%
- Education$855%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $222 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $165 |
| Biohaven Pharmaceuticals, Inc. | 6 | $163 |
| AbbVie(2 entities) | 9 | $159 |
| Johnson & Johnson | 5 | $159 |
| Avanir Pharmaceuticals, Inc. | 1 | $86 |
| Mannkind Corporation | 2 | $85 |
| SK Life Science, Inc. | 1 | $76 |
| Lilly USA, LLC | 4 | $67 |
| Pfizer | 4 | $66 |
| Bayer | 3 | $54 |
| Novo Nordisk | 2 | $38 |
| UCB, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 3 | $30 |
| AstraZeneca | 2 | $29 |
| GSK | 2 | $29 |
| Melinta Therapeutics, LLC | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| CMP Pharma, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Urovant Sciences Inc | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Smith+Nephew | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Evoke Pharma, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$239
How this compares
$1,796 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,737 | $479,640 |
| XareltoRivaroxaban | 620 | $177,442 |
| Austedo XrDeutetrabenazine | 20 | $140,711 |
| OzempicSemaglutide | 120 | $130,362 |
| XifaxanRifaximin | 53 | $109,438 |
| JardianceEmpagliflozin | 330 | $91,328 |
| TrulicityDulaglutide | 93 | $82,899 |
| MyrbetriqMirabegron | 277 | $62,407 |
| FarxigaDapagliflozin Propanediol | 182 | $59,966 |
| JanuviaSitagliptin Phosphate | 171 | $56,593 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $55,715 |
| Atorvastatin Calcium | 3,706 | $51,675 |
| TradjentaLinagliptin | 128 | $50,815 |
| LokelmaSodium Zirconium Cyclosilicate | 96 | $43,964 |
| Divalproex Sodium | 813 | $39,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $66 | $504,3451,816 claims |
| Johnson & JohnsonXarelto, Procrit | $159 | $200,302648 claims |
| Boehringer IngelheimJardiance, Tradjenta | $33 | $142,143458 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $13 | $140,71120 claims |
| Novo NordiskOzempic | $38 | $130,362120 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $222 | $109,43853 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $67 | $105,601115 claims |
| AstraZenecaFarxiga, Lokelma | $29 | $103,929278 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $29 | $92,204177 claims |
| Astellas Pharma US IncMyrbetriq | $11 | $62,407277 claims |
| AbbVieVraylar, Linzess | $159 | $61,30784 claims |
| AmgenProlia | $15 | $18,98511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Parma
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.